|Table of Contents|

Research progress of HER-2 alterations in targeted therapy of non-small cell lung cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 03
Page:
565-569
Research Field:
Publishing date:

Info

Title:
Research progress of HER-2 alterations in targeted therapy of non-small cell lung cancer
Author(s):
WU Mingshuang; LIU Jia; YANG Maopeng
Department of Medical Oncology,the Affiliated Tumor Hospital of Harbin Medical University,Heilongjiang Harbin 150081,China.
Keywords:
non-small cell lung cancer; HER-2; Pyrotinib; T-DM1; Tarloxotinib
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2024.03.033
Abstract:
Lung cancer is one of the malignant tumors with the highest degree of malignancy and mortality.Non-small cell lung cancer (NSCLC) accounts for about 85%.Targeted therapy is the preferred treatment option for NSCLC.Targeted therapies significantly improved clinical outcomes in ALK,ROS1,BRAF,NTRK,MET,and most NSCLC patients with EGFR mutations.However,the discovery that abnormally activated human epidermal growth factor receptor-2(HER-2) is resistant to EGFR inhibitors and is not sensitive to chemotherapy has prompted further research into targeted therapies for HER-2 altered NSCLC patients.HER-2 alterations include gene mutations,amplification and protein overexpression.Different types of HER-2 alterations target different targeted therapies, among which the HER-2 exon 20 mutation is the most important driver mutation with functional significance in NSCLC.In this paper,the research progress of targeted therapies for HER-2 altered NSCLC patients,such as Afatinib,Poziotinib,Pyrotinib,T-DM1 and Tarloxotinib was reviewed in detail.

References:

［1］CHEN Z,FILLMORE CM,HAMMERMAN PS,et al. Non-small-cell lung cancers:a heterogeneous set of disease［J］.Nat Rev Cancer,2014,14(8):535-546.
［2］WILDING BIRGIT,SCHARN DIRK,DIETRICH,et al.Discovery of potent and selective HER-2 inhibitors with efficacy against HER-2 exon 20 insertion-driven tumors,which preserve wild-type EGFR signaling［J］.Nat Cancer,2022,3(12):821-836.
［3］TAKAKURA TOSHIAKI,YAMAMOTO NOBUYUKI.Treatment of non-small cell lung cancer with HER-2 alterations［J］.Gan To Kagaku Ryoho,2023,50(11):768-772.
［4］ARCILA ME,CHAFT JE,NAFA K,et al.Prevalence,clinicopathologic associations,and molecular spectrum of erbb2 (HER-2) tyrosine kinase mutations in lung adenocarcinomas［J］.Clinical Cancer Research An Official Journal of the American Association for Cancer Research,2012,18(18):4910-4918.
［5］DE TOMA ALESSANDRO,LO RUSSO GIUSEPPE,SIGNORELLI DIEGO,et al.Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake［J］.Crit Rev Oncol Hematol,2021,160(10):103-109.
［6］CHUANG JC,STEHR H,LIANG Y,et al.ERBB2-mutated metastatic non-small-cell lung cancer:response and resistance to target therapies［J］.Thorac Oncol,2017,12(5):833-842.
［7］KIM JEHUN,JANG TAE WON,CHOI CHANG MIN,et al.EGFR real-world analysis of first-line afatinib in patients with -mutant non-small cell lung cancer and brain metastasis:survival and prognostic factors［J］.Transl Lung Cancer Res,2023,12(17):1197-1209.
［8］PARK K,TAN EH,O'BYRNE K,et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7):a phase 2B,open-label, randomised controlled trial［J］.Lancet Oncol,2016,17(5):577-589.
［9］MAZIERES J,PETERS S,LEPAGE B,et al.Lung cancer that harbors an HER-2 mutation: epidemiologic characteristics and therapeutic perspectives［J］.J Clin Oncol,2013,31(16):1997-2003.
［10］MAZIèRES J,BARLESI F,FILLERON T,et al.Lung cancer patients with HER-2 mutations treated with chemotherapy and HER-2-targeted drugs:results from the European EUHER-2 cohort［J］.J Thorac Oncol,2018,13(9):23-26.
［11］LAI W VICTORIA,LEBAS LOUISIANE,BARNES TRISTAN A ,et al.Afatinib in patients with metastatic or recurrent HER-2-mutant lung cancers: a retrospective international multicentre study［J］.Eur J Cancer,2019,109(2):28-35.
［12］DZIADZIUSZKO RAFAL,SMIT EGBERT F,DAFNI URANIA,et al. Afatinib in NSCLC with HER-2 mutations:results of the prospective, open-label phase II niche trial of european thoracic oncology platform (ETOP)［J］.J Thorac Oncol,2019,14(6): 1086-1094.
［13］ELAMIN YASIR Y,ROBICHAUX JACQULYNE P,CARTER BRETT W,et al. Poziotinib for EGFR exon 20-mutant NSCLC:clinical efficacy,resistance mechanisms,and impact of insertion location on drug sensitivity［J］.Cancer Cell,2022,40(6):754-767.
［14］HEYMACH J,NEGRAO M,ROBICHAUX JP,et al.A phase II trial of poziotinib in EGFR and HER-2 exon 20 mutant non-small cell lung cancer (NSCLC)［J］.J Thorac Oncol,2018,13(9):23-26.
［15］GAO G,LI X,WANG Q,et al.Single-arm,phase II study of pyrotinib in advanced non-small cell lung cancer (NSCLC) patients with HER-2 exon 20 mutation［J］.Journal of Clinical Oncology,2019,37(15):9089.
［16］PRELAJ A,BOTTIGLIERI A,PROTO C,et al. Poziotinib for EGFR and HER-2 exon 20 insertion mutation in advanced NSCLC:results from the expanded access program［J］.European Journal of Cancer,2021,149(9):235-248.
［17］AWAD MM,OXNARD GR,JACKMAN DM,et al. MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent met genomic amplification and c-met overexpression［J］.Journal of Clinical Oncology,2016,34(7):721-730.
［18］METRO G,BAGLIVO S,MORETTI R,et al. Is there a role for multiple lines of Anti-HER-2 therapies administered beyond progression in HER-2-mutated non-small cell lung cancer a case report and literature review［J］.Oncol Ther,2020,8(2):341-350.
［19］PIOTROWSKA Z,WANG Y,SEQUIST LV,et al.ECOG-ACRIN 5162:a phase II study of osimertinib 160 mg in NSCLC with EGFR exon 20 insertions［J］.Journal of Clinical Oncology,2020,38(15):9513.
［20］LIU SI-YANG MAGGIE,TU HAI-YAN,WEI XUE-WU,et al. First-line pyrotinib in advanced HER-2-mutant non-small-cell lung cancer:a patient-centric phase 2 trial［J］.Nat Med,2023,29(18):2079-2086.
［21］MAO SHIQI,LUO LIBO,YANG SHUO,et al.Outcome comparison of pyrotinib with current standard of care in the second/third line setting in advanced non-small cell lung cancer patients with HER-2 mutation［J］.Chin Med J (Engl),2023,136(7): 848-850. ［22］WANG Y,JIANG T,QIN Z,et al. HER-2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib［J］.Annals of Oncology,2019,30(3):447-455.
［23］ZHOU CC,LI XY,WANG QM,et al. HER-2 pyrotinib in -mutant advanced lung adenocarcinoma after platinum-based chemotherapy:a multicenter,open-label,single-arm, phase II study［J］.J Clin Oncol,2020,38(24):2753-2761.
［24］NI J,SI XY,ZHANG L.Non-small-cell lung cancer with ERBB2 mutation in non-tyrosine kinase domain benefits from pyrotinib: a case report［J］.Thorac Cancer,2021,12(8):1244-1247.
［25］ZHANG XY,LV JL,WU YH,et al. HER-2 exon 20 insertion mutations in lung adenocarcinoma: case series and response to pyrotinib［J］.Front Oncol,2020,31(10):1162.
［26］KAYATANI H,OHASHI K,NINOMIYA K,et al.Beneficial effect of erlotinib and trastuzumab emtansine combination in lung tumors harboring EGFR mutations［J］.Biochem Biophys Res Commun,2020,532(3):341-346.
［27］PETERS S,STAHEL R,BUBENDORF L,et al.Trastuzumab emtansine (T-DM1) in patients with previously treated HER-2- overexpressing metastatic non-small-cell lung cancer:efficacy,safety and biomarkers［J］.Clin,Cancer Res,2019,25 (1):64-72.
［28］LI BT,SHEN R,BUONOCORE D,et al.Ado-trastuzumab emtansine for patients with HER-2-mutant lung cancers:results from a phase II basket trial［J］.J Clin Oncol,2018,36(24):2532-2537.
［29］HOTTA K,AOE K,KOZUKI T,et al. A phase II study of trastuzumab emtansine in HER-2-positive non-small cell lung cancer［J］.J Thorac Oncol,2018,13(2):273-279.
［30］KOGA TAKAMASA,SUDA KENICHI,NISHINO MASAYA,et al.HER-2 activity and mechanism of acquired resistance to tarloxotinib in mutant lung cancer:an study［J］.Transl Lung Cancer Res,2021,10(8):3659-3670.
［31］MCLEAN LUKE S,MORRIS TESSA A,GRAMZA ANN,et al.A phase II study of tarloxotinib (a hypoxia activated prodrug of a pan-erb tyrosine kinase inhibitor) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or skin［J］.Invest New Drugs,2022,40(8):782-788.
［32］NISHINO M,SUDA K,KOGA T,et al.Activity of tarloxotinib-E in cells with EGFR exon-20 insertion mutations and mechanisms of acquired resistance［J］.Thorac Cancer,2021,12(10):1511-1516.
［33］LIU SV,VILLARUZ LC,LEE VHF,et al.LBA61 first analysis of RAIN-701:study of tarloxotinib in patients with non-small cell lung cancer (NSCLC) EGFR exon 20 insertion,HER-2-activating mutations & other solid tumours with NRG1/ERBB gene fusions［J］.Ann Oncol,2020,31(4):1189.
［34］ESTRADA-BERNAL A,LE AT,DOAK AE,et al.Tarloxotinib is a hypoxia-activated Pan-HER kinase inhibitor active against a broad range of her-family oncogenes［J］.Clin Cancer Res,2021,27(5):1463-1475.
［35］ISE N,OMI K,NAMBARA D,et al.Overexpressed HER-2 in NSCLC is a possible therapeutic target of EGFR inhibitors［J］.Anticancer Res,2011,31(12):4155-4161.
［36］CHEN D,CHU T,CHANG Q,et al.The relationship between preliminary efficacy and prognosis after first-line EGFR tyrosine kinase inhibitor (EGFR-TKI) treatment of advanced non-small cell lung cancer［J］.Ann Transl Med,2019,7(9):195-199.

Memo

Memo:
-
Last Update: 2023-12-29